



DTAus – ASM 2025

The new era in AD therapies

Date: Friday 10 October 2025

Time: 10:00AM-5:00PM

Location: Parkroyal Darling Harbour, NSW

Conference Program

Time	Topic
09:00 - 10:00 AM	Registration/Welcome Tea & Coffee
10:00 - 10:05 AM	Conference Opening Dr Chrys Pulle
10:05 - 10:20 AM	CEO of Dementia Australia Professor Tanya Buchanan
10:20 - 10:35 AM	Consumer Voice Bill Yeates
10:35 - 11:05 AM	Pre-Clinical AD Professor Colin Masters
11:05 - 11:35 PM	Roche Diagnostics: AD BioMarkers Professor Christopher Rowe
11:35 - 12:05 PM	Novo Nordisk: Metabolic and Physiological Changes in Dementia and the Potential Role of GLP1 A/Prof. Rebekah Ahmed
12:10 - 12:55 PM	LUNCH
1:00 - 1:15 PM	DTAus AGM DTAus Executive
1:15 - 1:40 PM	Trials Update A/Prof. Kathryn Goozee
1:40 - 2:10 PM	How TGA determines how to register a new drug A/Prof. Mark Yates
2:10 - 2:40 PM	Lilly: Donanemab in Early Symptomatic Alzheimer's Disease: Efficacy and Safety from the TRAILBLAZER-ALZ 2 Long-Term Extension A/Prof. Paul Yates
2:40 - 3:10 PM	Eisai: What can we learn from monoclonal antibodies and oncology? Professor David Thomas
3:10 - 3:25 PM	Kinox Therapeutics: Development of KNX100: Treatment of Agitation in Dementia. Professor Michael Bowen
3:25 - 3:40 PM	AFTERNOON TEA
3:40 - 4:05 PM	Being Bloody-Minded About Alzheimer's: Challenging the Brain-Centric View Professor John Mamo
4:05 - 4:30 PM	ADNet & Potential pathways of ATT A/Prof. Paul Yates
4:30 - 4:55 PM	Hot Topics/Breaking Updates A/Prof. Michael Woodward
4:55 - 5:00 PM	Closing



DTAus

DTAus Chair

Dr Chrys Pulle

ChrysRanjeev.Pulle@health.qld.gov.au

DTAus Executive

Professor Christopher Rowe

Dr Paul Yates

Dr Cathy Short

A/Prof. Michael Woodward

A/Prof. Roger Clarnette

A/Prof. Kathryn Goozee

Dr Ishita Batta

Dr Sally Johns

Dr Nigel Gilchrist

Professor Philip Morris

Demi Rozakis

Zandy Rwodzi

Renate Thienel

Professor. Michael Breakspear



Diagnostics



Registration Details

DTAus Annual Scientific Meeting, Parkroyal Darling Harbour
10th October, 2025

Face to Face Registration Fee: \$200

Registration Link: <https://www.trybooking.com/DBYNZ>

Dr Chrys Pulle, MB BS FRACP (Chair)

Conference Opening

Staff Specialist Geriatrician and Director Internal Medicine Dementia Research Unit at The Prince Charles Hospital, Metro North Hospital and Health Service, QLD Health.

Other appointments:

- Chair of Dementia Trials Australia 2019 – current.
- President of the QLD Div ANZSGM 2017 – current.
- Co chair Australasian Consortium of Centres for Clinical Cognitive Research 2016-2018.
- Senior Lecturer, Northside Clinical School University of QLD
- Chair Network of Fracture Education and Research, The Prince Charles Hospital.



Professor Tanya Buchanan BA(Hons), BSc(Nsg), DipPM, MBA, PhD, GAICD

Dementia Australia



Prof Buchanan is CEO of Dementia Australia. She has held previous CEO roles with Cancer Council Australia, the Thoracic Society of Australia and New Zealand and Action on Smoking and Health in Wales (UK). Prof Buchanan is an Honorary Professor of Practice in the School of Health and Society (Public Health) at the University of Wollongong and is an Adjunct Professor in Dementia & Health Policy at Curtin University.

Professor Buchanan studied Nursing at Curtin University of Technology and an MBA in Health Services at Edith Cowan University. She also holds a PhD and a range of qualifications including governance qualifications from the Australian Institute of Company Directors (GAICD). Professor Buchanan commenced her career as a Registered Nurse with clinical work in neuroscience, and has worked in health, academia, local government and the voluntary sector. She is active in public health research and practice.

Bill Yeates

Consumer Voice

After graduating in Pharmacy, Bill Yeates spent over 35 years teaching senior Physics and Chemistry and working as a school administrator. In 2019, at the age of 59, he was diagnosed with Younger Onset Alzheimer's disease. Determined to live a more enjoyable and meaningful life, Bill created a holistic, person-centred approach called The Tree of Awakening Your Positivity and shares his experiences through his website, national/international speaking engagements, and advocacy work. A passionate surf lifesaver and master's competitor in swimming, surf lifesaving and finswimming, Bill is currently involved in producing a short film series, Navigating Life with Dementia and a Reablement App.



Bill is a Living Experience Associate Consultant for HammondCare, a non-executive director of MADEC Ltd, and an active member of multiple advisory panels, including Dementia Australia's Advocate Program, World Health Organization's Global Dementia Observatory Knowledge Exchange and ADI's Global Dementia Accreditation Panel. Besides being a participant in a phase 1b and 2 clinical trial, Bill is also involved in dementia research as an Associate Investigator and co-author. Bill was elected as a Board member of ADI in July 2025.

Professor Colin Masters BMedSc (Hons), MBBS, MD, Hon.DLitt, AO

Pre-Clinical Alzheimer's Dementia



Colin Masters has focused his career on research in Alzheimer's disease and other neurodegenerative diseases, including Creutzfeldt-Jakob disease. His work over the last 40 years is widely acknowledged as having had a major influence on Alzheimer's disease research world-wide, particularly the collaborative studies conducted with Konrad Beyreuther in which they discovered the proteolytic neuronal origin of the A β amyloid protein which causes Alzheimer's disease. This work has led to the continued development of diagnostics and therapeutic strategies.

- More recently, his focus has been on describing the natural history of Alzheimer's disease as a necessary preparatory step for therapeutic disease modification. Professor Masters is currently a Professor at the Florey Institute, the University of Melbourne. He is also a consultant at the Royal Melbourne Hospital. His achievements have been recognised by the receipt of many international awards.

Professor Christopher Rowe (BMBS, FRACP, MD, FAANMS)

Roche Diagnostics: Alzheimer's Dementia BioMarkers

Director of Molecular Imaging Research at Austin Health and the University of Melbourne, VIC.

- Christopher Rowe is a nuclear medicine physician and neurologist, with over 20 years of experience in dementia research and patient care.

He is the Principal Investigator and Director of the Australian Dementia Network (ADNeT) established across the nation in late 2018 with funding from the Federal Government through the NHMRC National Institute of Dementia Research and philanthropic donors. His research focus is molecular brain imaging of neurodegenerative diseases, particularly Alzheimer's disease, for better understanding, earlier more accurate detection, and to facilitate development of early therapeutic interventions.

He is a 2019 Highly Cited Researcher (top 1% world-wide for neuroscience) and has received international awards for his work including the US Society of Nuclear Medicine Kuhl-Lassen Award for Outstanding Contribution to Brain Imaging and the Christopher Clark Award for advancing human amyloid imaging.



Associate Professor Rebekah Ahmed (PhD)

Novo Nordisk: Metabolic and Physiological Changes in Dementia and the Potential Role of GLP1



Assoc. Professor Rebekah Ahmed is a Staff specialist Neurologist at Royal Prince Alfred Hospital and University of Sydney, where she directs the multidisciplinary Memory and Cognition Clinic. She graduated from Medicine at the University of Adelaide (University Medal) and completed her Neurology training at Royal Prince Alfred Hospital and Concord Hospital. She was awarded the Australian and New Zealand Association of Neurology Fellowship to the National Hospital of Neurology and Neurosurgery, Queen Square, London. She also completed a Clinical Research Fellowship at the Dementia Research Centre, University College London. Her PhD focused on eating and metabolic abnormalities in Frontotemporal dementia (FTD) and Amyotrophic lateral sclerosis. She is a clinician scientist with her research focusing on metabolic biomarkers in neurodegeneration. She runs a number of clinical trials in Alzheimer's disease and gene therapy in FTD. She is Block Chair for Neurology in the University of Sydney Medical Program.

Associate Professor Paul Yates

Lilly: Donanemab in Early Symptomatic Alzheimer's Disease: Efficacy and Safety from the TRAILBLAZER-ALZ 2 Long-Term Extension
ADNet & Potential Pathways of ATT

Associate Professor Paul Yates is a geriatrician and clinician-researcher with expertise in dementia and geriatric medicine in hospital and community settings. He is Acting Director of Research, Continuing Care Division, Austin Health, and Acting Director of the Cognitive, Dementia and Memory Service, as well as Clinical Associate Professor with the University of Melbourne Department of Medicine, Austin Health.

He has extensive experience as Principal or Sub-Investigator on >20 clinical trials in AD (>18 monoclonal antibody trials) and is Lead National PI and highest recruiting Australian site for the pivotal CLARITY and AHEAD Studies of Lecanemab in symptomatic and preclinical AD. He has >\$7 million in competitive funding as CI in the last 5 years, >50 conference presentations, 43 publications and two book chapters.

He has developed educational material for Dementia Australia and supervised numerous PhD and DMedSci students, as well as >25 Geriatric Medicine Advanced Trainee projects and >20 Doctor of Medicine Research Project students. He is on the ANZSGM Scientific Advisory Committee, Steering Committee of the Melbourne Ageing Research Collaboration and Melbourne Academic Centre for Health Care of the Ageing Subcommittee and served as MACH representative to the Australian Health Research Alliance Consumer and Community Involvement Steering Committee.



Professor David Thomas

Eisai: What can we learn from monoclonal antibodies and oncology?



Professor David Thomas is a globally recognised clinician-scientist and the founding force behind Omico and the ProSPeCT initiative. He is the inaugural Director of the Centre for Molecular Oncology at UNSW and formerly served as Director of the Kinghorn Cancer Centre and Head of the Cancer Division at the Garvan Institute of Medical Research (2014–2021). He founded the Australasian Sarcoma Study Group and the International Sarcoma Kindred Study—the largest global investigation of heritable risk in sarcoma—spanning 23 centres across seven countries. Prof Thomas led the landmark denosumab study in Giant Cell Tumour of Bone, resulting in FDA, EMA, and TGA approval and PBS reimbursement, and co-led the pivotal meta-analysis of whole-body MRI screening in Li-Fraumeni syndrome, which drove changes to international guidelines and led to an MBS listing.

As the founder of Omico, Australia's national genomic cancer medicine centre, he has enabled access to genomic profiling and matched therapies for over 25,000 Australians. With more than 280 publications—including in Science, Cancer Cell, JAMA Oncology, and Lancet Oncology—and an H-index of 60, Prof Thomas continues to shape global policy and clinical standards.

Associate Professor Kathryn Goozee

Clinical Trials Update



Associate Professor Kathryn Goozee is a Nurse Practitioner with extensive expertise in dementia prevention, diagnosis, research, and care, combining academia with clinical services. Kathryn holds a Graduate Diploma in Gerontology, a Master's in Clinical Nursing, and a PhD in Neuroscience from the University of Western Australia, having conducted a landmark clinical trial in Alzheimer's disease prevention, utilising Blood biomarkers, and PET amyloid imaging outcomes within 105 at risk older people.

Kathryn is the Owner and Director of the KaRa Institute of Neurological Diseases (KaRa MINDS), a leading dementia-focused clinical trials facility in Macquarie Park, Sydney, which has conducted more than 45 trials over the past decade. She has authored more than 40 publications, contributed to Understanding Alzheimer's Disease, and is a sought-after speaker for her ability to translate complex science into clear and engaging language. Kathryn is an invited opinion leader for several pharmaceutical organisations, a Board Member for Scalabrini Villages NSW; a Member of the Macquarie University Dementia Research Centre; and a research grant committee member, for the Dementia Research Community, raising funds for dementia research.

Associate Professor Michael Woodward

Alzheimer's Dementia

Associate Professor Michael Woodward is Head of Aged Care Research and the Memory Clinic at Austin Health in Melbourne, Victoria, and an Honorary Medical advisor for Dementia Australia. He is a specialist in geriatric medicine with major interests in the treatment of Alzheimer's disease (AD) and other dementias. He is Principal Investigator for numerous research trials of new therapies for AD and related disorders. He is Past President of the AC4R – the Australasian Consortium of Centres for Clinical Cognitive Research that brings together researchers into therapeutic agents for dementia. He was a member of the Alzheimer's Australia Victoria Board, being appointed their chief medical advisor and chairing their research foundation, which administers over \$2 million of research funding.



Michael Woodward's publication record includes over 120 original research and review articles. He has been awarded his MD on the overlap between the dementia syndromes. More recent research interests have focused on characterizing the frontal variant of Alzheimer's Disease. He is a Fellow of the Australian Association of Gerontology (AAG), the Australian and New Zealand Society for Geriatric Medicine, the Australian Wound Management Association (AWMA) and the Royal Australasian College of Physicians (RACP) and has long served each of these professional bodies, including becoming President of AWMA and AAG (Vic) and chairing the Committee for Physician Training that oversaw the training of all RACP trainees.

Professor Michael Bowen

Kinox Therapeutics: Development of KNX100: Treatment of Agitation in Dementia



Professor Michael Bowen is co-founder and Chief Scientific Officer of biotech company Kinox Therapeutic and Professor of Translational Neuroscience and Psychopharmacology at the University of Sydney. Kinox are developing novel therapeutics for disorders of the brain and mind, and Michael is co-inventor of the Kinox lead compound, KNX100. KNX100 is in clinical development, has successfully complete phase 1 clinical trials, and is in phase 2 clinical trials for the treatment of agitation and aggression associated with dementia. In addition to the KNX100 series program, Kinox Therapeutics has a preclinical program developing novel small molecules targeting the oxytocin receptor in partnership with Boehringer Ingelheim.

In recognition of his work discovering and developing novel therapeutics and for his achievements translating and commercialising research, Michael has received numerous honours, including the 2021 Prime Minister's Prize for New Innovators and a 2016 Eureka Prize.

Professor John Mamo

Being Bloody-Minded About Alzheimer's: Challenging the Brain-Centric View

John Mamo is a John Curtin Distinguished Professor at Curtin University and Head of the Neurovascular and Metabolic Diseases Domain at the Perron Institute for Neurological and Translational Sciences. With more than 35 years in medical research, he has led landmark preclinical and clinical studies in cardiometabolic and neurodegenerative disorders—including Alzheimer's, Parkinson's and multiple sclerosis—as well as pain conditions such as migraine and endometriosis. Relevant to his DTAus presentation, his pioneering research revealed a blood-to-brain pathway for late-onset Alzheimer's disease, driven by lipoprotein-amyloid/capillary interactions, for which he received the NHMRC's highest accolade, the Marshall and Warren Award for Innovative and Transformative Science. His work has identified novel neurovascular protective interventions and informed the development of new neuroprotective drug analogues



Associate Professor Mark Yates

How TGA determines how to register a new drug & The Pharmaceutical Benefit Advisory Scheme



Mark is a consultant Geriatrician in the Cognitive, Dementia and Memory Service (CDAMS), the Residential in Reach Service and the Hospital in the Home Program at Grampians Health, Ballarat and Clinical Associate Professor at Deakin University. He is a CI for the MRFF funded Dementia Together Study and AI in the CREEDD study.

Mark is a member of the team at Grampians Health that developed the Dementia Care in Hospitals Program, which is an all of hospital education program linked to a bedside cognitive impairment alert the Cognitive Impairment Identifier (CII). The DCHP has been rolled out and evaluated in 8 states and territories and the CII is recognised as a national symbol for cognitive impairment in hospitals.

He is a member of the Ministers Dementia Expert Reference Group and the National Aged Care Advisory Council. He is past member of the National Commission for Safety and Quality in Health Care's Cognitive Impairment Advisory Group, the Pharmaceutical Benefits Advisory Committee and a past President of AMA Victoria.